Global siRNA Drugs Market Growth (Status and Outlook) 2024-2030

Global siRNA Drugs Market Growth (Status and Outlook) 2024-2030

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA at first non-coding RNA molecules, typically 20–24 (normally 21) base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. siRNA plays a crucial role in gene silencing and regulation of gene expression. siRNA-based therapeutics have gained significant attention in recent years due to their potential to target specific genes involved in diseases such as cancer, genetic disorders, viral infections, and neurodegenerative diseases. The scope of siRNA drug products encompasses various aspects, including their design, development, testing, and regulatory approval.

The global siRNA Drugs market size is projected to grow from US$ 2391 million in 2024 to US$ 13310 million in 2030; it is expected to grow at a CAGR of 33.1% from 2024 to 2030.

LPI (LP Information)' newest research report, the “siRNA Drugs Industry Forecast” looks at past sales and reviews total world siRNA Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected siRNA Drugs sales for 2023 through 2029. With siRNA Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world siRNA Drugs industry.

This Insight Report provides a comprehensive analysis of the global siRNA Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on siRNA Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global siRNA Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for siRNA Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global siRNA Drugs.

Core manufacturers of siRNA Drugs include Alnylam, Novartis, Novo Nordisk, Genzyme and Arrowhead. USA is the largest consumption region, accounting for approximately 57% of the global market, followed by Europe. In terms of product type, subcutaneous injection are the largest market segment, with a share of more than 77%. In terms of product application, the largest application market is nervous system therapy, with a share of approximately 52%.

This report presents a comprehensive overview, market shares, and growth opportunities of siRNA Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Intravenous Injection
Subcutaneous Injection

Segmentation by Application:
Nervous System Therapy
Endocrine and Metabolic Therapy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Intravenous Injection
Subcutaneous Injection

Segmentation by Application:
Nervous System Therapy
Endocrine and Metabolic Therapy
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alnylam
Novartis
Novo Nordisk
Genzyme
Arrowhead
Silence
Sylentis
Avidity Biosciences
Sirnaomics

Please note: The report will take approximately 2 business days to prepare and deliver.